Healthcare provider profile · identity verified

Lance C Larson, MD

Internal Medicine · BELLEVUE, WA · NPI 1851310510

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	543	162
Amlodipine Besylate	Amlodipine Besylate	434	129
Rosuvastatin Calcium	Rosuvastatin Calcium	320	106
Losartan Potassium	Losartan Potassium	262	78
Lisinopril	Lisinopril	233	68
Tamsulosin Hcl	Tamsulosin Hcl	229	70
Hydrochlorothiazide	Hydrochlorothiazide	205	64
Levothyroxine Sodium	Levothyroxine Sodium	191	56
Atenolol	Atenolol	151	37
Allopurinol	Allopurinol	144	35
Gabapentin	Gabapentin	144	48
Simvastatin	Simvastatin	138	40
Metoprolol Succinate	Metoprolol Succinate	128	37
Irbesartan	Irbesartan	127	33
Sertraline Hcl	Sertraline Hcl	124	31
Metformin Hcl Er	Metformin Hcl	115	35
Omeprazole	Omeprazole	104	37
Eliquis	Apixaban	86	25
Potassium Chloride	Potassium Chloride	86	21
Trazodone Hcl	Trazodone Hcl	82	27
Lovastatin	Lovastatin	81	20
Donepezil Hcl	Donepezil Hcl	79	23
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	77	18
Jardiance	Empagliflozin	74	18
Finasteride	Finasteride	63	18
Pravastatin Sodium	Pravastatin Sodium	60	15
Pantoprazole Sodium	Pantoprazole Sodium	54	17
Famotidine	Famotidine	51	14
Telmisartan	Telmisartan	47	19
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	44	14
Fluoxetine Hcl	Fluoxetine Hcl	41	12
Glimepiride	Glimepiride	40	11
Ipratropium Bromide	Ipratropium Bromide	40	suppressed
Memantine Hcl	Memantine Hcl	40	11
Metformin Hcl	Metformin Hcl	40	12
Albuterol Sulfate Hfa	Albuterol Sulfate	38	24
Ozempic	Semaglutide	38	suppressed
Bupropion Xl	Bupropion Hcl	35	13
Escitalopram Oxalate	Escitalopram Oxalate	33	suppressed
Furosemide	Furosemide	32	suppressed
Valacyclovir	Valacyclovir Hcl	31	18
Oxybutynin Chloride Er	Oxybutynin Chloride	30	suppressed
Acyclovir	Acyclovir	29	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	29	suppressed
Valsartan	Valsartan	27	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	27	15
Triamcinolone Acetonide	Triamcinolone Acetonide	26	16
Duloxetine Hcl	Duloxetine Hcl	25	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	24	23
Fluticasone Propionate	Fluticasone Propionate	24	15
Prednisone	Prednisone	24	16
Clopidogrel	Clopidogrel Bisulfate	23	suppressed
Alendronate Sodium	Alendronate Sodium	22	suppressed
Spironolactone	Spironolactone	22	suppressed
Xarelto	Rivaroxaban	22	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	21	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	21	21
Ezetimibe	Ezetimibe	19	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	19	suppressed
Colchicine	Colchicine	18	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	18	suppressed
Diclofenac Sodium	Diclofenac Sodium	17	12
Doxycycline Monohydrate	Doxycycline Monohydrate	17	16
Dutasteride	Dutasteride	17	suppressed
Estradiol	Estradiol	17	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	17	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	16	15
Trulicity	Dulaglutide	16	suppressed
Benazepril Hcl	Benazepril Hcl	14	suppressed
Meloxicam	Meloxicam	14	suppressed
Ramipril	Ramipril	14	suppressed
Bupropion Hcl Sr	Bupropion Hcl	13	suppressed
Carvedilol	Carvedilol	13	suppressed
Klor-Con M20	Potassium Chloride	13	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	13	suppressed
Potassium Citrate Er	Potassium Citrate	13	suppressed
Torsemide	Torsemide	13	suppressed
Azithromycin	Azithromycin	12	11
Fenofibrate	Fenofibrate	12	suppressed
Mupirocin	Mupirocin	12	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	11	suppressed
Bydureon Bcise	Exenatide Microspheres	11	suppressed
Lactulose	Lactulose	11	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	11	suppressed
Synthroid	Levothyroxine Sodium	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error